Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Cytokinetics (NASDAQ: CYTK).The analyst commented, “EDG-7500 shows signs of activity ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE